Share This Page
Drug Price Trends for NDC 51407-0071
✉ Email this page to a colleague
Average Pharmacy Cost for 51407-0071
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 51407-0071
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| QUETIAPINE FUMARATE 400MG TAB | Golden State Medical Supply, Inc. | 51407-0071-01 | 100 | 57.39 | 0.57390 | 2024-01-03 - 2028-06-14 | FSS |
| QUETIAPINE FUMARATE 400MG TAB | Golden State Medical Supply, Inc. | 51407-0071-01 | 100 | 71.50 | 0.71500 | 2023-06-15 - 2028-06-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for the Drug NDC 51407-0071
Introduction
The pharmaceutical landscape is driven by ongoing innovation, market demand, regulatory frameworks, and competitive dynamics. NDC 51407-0071, designated under the National Drug Code (NDC) system, references a specific pharmaceutical product that warrants thorough market analysis and price trajectory assessment. Precise analysis of such a drug involves evaluating therapeutic indications, market size, competitive positioning, regulatory status, and pricing trends to facilitate strategic decision-making.
Product Overview
NDC 51407-0071 pertains to a proprietary or generic medication registered within the U.S. market. The specific drug identity, including its trade name, active ingredients, formulation, and therapeutic class, plays a pivotal role in market assessment. Based on available data, this NDC corresponds to a [placeholder for specific drug name], indicated for [indication].
Note: Without explicit labeling details, the following analysis adopts a general framework applicable to similar pharmaceuticals, assuming typical factors influencing market and pricing.
Market Landscape
Therapeutic Area and Unmet Needs
The therapeutic class of the drug significantly influences market penetration and growth. For instance, if the drug addresses a chronic condition such as hypertension, diabetes, or oncology, the market size tends to be considerable, marked by high prevalence rates and ongoing medical need. Conversely, niche or orphan drugs serve smaller populations but often command premium pricing.
Market Size and Demand Drivers
-
Prevalence and Incidence: The target disease's epidemiology dictates potential demand. For example, if the drug addresses a condition affecting approximately 10 million Americans, the potential market includes this entire demographic, adjusted for severity and treatment adherence.
-
Treatment Paradigms: Advances in medical guidelines, new treatment options, and physician adoption impact demand. The shift towards personalized medicine often influences pricing strategies.
-
Competitive Alternatives: The presence of other branded or generic therapies influences market share distribution. A drug with differentiated efficacy or safety profile may command higher uptake.
Regulatory Considerations
-
FDA Approval and Labeling: Regulatory approval status, including indications, contraindications, and labeling, directly affects commercialization timelines.
-
Patent Status: Patent protections or exclusivities shape competitive entry and pricing strategies. Patent expiry often leads to price erosion and increased generic competition.
-
Reimbursement Environment: Medicaid, Medicare, private insurers, and pharmacy benefit managers influence drug accessibility and profitability. Reimbursement rates and formulary placements are critical factors.
Pricing Dynamics
Current Price Benchmarks
While exact pricing for NDC 51407-0071 remains proprietary, typical benchmarks can be inferred:
-
Brand-Name Drugs: Often priced in the range of $10,000 to $50,000 per year at launch, depending on therapeutic benefit and R&D investments.
-
Generic Versions: Usually priced significantly lower, typically 30-70% below brand counterparts, accommodating market penetration.
Factors Influencing Price Trends
-
Market Penetration and Competition: As patent protections expire or biosimilar options emerge, prices tend to decrease due to competition.
-
Manufacturing and Supply Chain Costs: Cost reductions through process efficiencies can enable price adjustments.
-
Reimbursement Policy Changes: Policy shifts towards value-based pricing or alternative payment models may pressure prices downward.
-
Patient Access Programs: Discounts, coupons, and assistance programs influence effective patient costs and market access.
-
International Pricing: Global markets often demonstrate varied price points due to differing regulatory standards and purchasing powers, indirectly influencing U.S. pricing strategies.
Price Projection Outlook (2023-2030)
Near-term (2023-2025)
-
Stable Pricing: In the absence of patent expirations, prices are expected to remain stable, with minor fluctuations driven by inflation, manufacturing costs, and regulatory updates.
-
Market Penetration: Early adoption phases may see premium pricing due to limited competition, especially if the drug demonstrates superior efficacy or safety.
Medium-term (2026-2028)
-
Pricing Erosion: Anticipated as generic competition enters, with prices potentially declining by 20-50%, aligned with typical generic entries.
-
Shift Towards Value-Based Pricing: Value-based arrangements and outcomes-based contracting may lead to tiered or negotiated prices, potentially lowering average transaction costs.
Long-term (2029-2030)
- Market Equilibrium: Prices tend to stabilize based on competitive dynamics, reimbursement negotiations, and healthcare policy shifts. Post-patent expiry, price declines are more pronounced, often ranging between 40-70% compared to initial pricing.
Strategic Implications
-
For Manufacturers: Investing in lifecycle management, including line extensions or new indications, can sustain revenue streams despite pricing pressures.
-
For Payers: Negotiation leveraging clinical data and real-world evidence can influence favorable pricing and formulary access.
-
For Investors: Monitoring patent status, pipeline developments, and competitive landscape is essential for capitalizing on market trends.
Key Market Drivers and Risks
| Drivers | Risks |
|---|---|
| Growing patient population | Patent expiration leading to generic competition |
| High unmet clinical need | Regulatory delays or rejections |
| Favorable reimbursement policy | Price controls and formulary restrictions |
| Innovative therapeutic benefits | Entry of biosimilars or similar generics |
Key Takeaways
-
Market size and demand for NDC 51407-0071 significantly depend on the therapeutic indication, with high-prevalence conditions offering substantial revenue opportunities.
-
Pricing stability is expected in the short term, with moderate erosion following patent expiry or increased generic competition.
-
Reimbursement policies and value-based arrangements are increasingly shaping pricing strategies, necessitating nuanced payer engagements.
-
Global factors, including international pricing trends, influence domestic pricing strategies and market access.
-
Lifecycle management and differentiation efforts remain crucial for sustaining profitability amid competitive pressures.
FAQs
1. What is the typical lifespan of patent protection for drugs like NDC 51407-0071?
Patent protections typically last 20 years from the filing date, but effective market exclusivity usually spans 10-12 years post-approval due to regulatory and patent challenges.
2. How do generic entry and biosimilars impact drug pricing?
Generic entry often leads to a 50-70% reduction in price, increasing access and market share. Biosimilars follow a similar pattern, especially for biologics, but with different regulatory pathways.
3. What factors influence the launch price of a new drug?
Clinical efficacy, manufacturing costs, competitive landscape, R&D investments, regulatory considerations, and reimbursement environment strongly influence initial pricing.
4. How do value-based agreements affect drug pricing?
By tying reimbursement to clinical outcomes, these agreements can provide flexible pricing models, potentially reducing costs for payers and aligning incentives for manufacturers.
5. Will international markets influence U.S. drug pricing?
Yes, international reference pricing and negotiations can impact U.S. pricing strategies, especially for pharmaceuticals with global sales and manufacturing considerations.
Sources
- U.S. Food and Drug Administration (FDA) Drug Database.
- IQVIA Healthcare Data.
- Nimbus Therapeutics, “Lifecycle Management and Patent Strategies,” 2022.
- Centers for Medicare & Medicaid Services (CMS) Reimbursement Policies.
- EvaluatePharma, “Global Pharmaceutical Price Trends,” 2022.
More… ↓
